Koyfin Home > Directory > Health Care > Adamas Pharma > Gross Margin

Adamas Pharma Gross Margin Chart (ADMS)

Adamas Pharma annual/quarterly Gross Margin from 2012 to 2020. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • Adamas Pharma Gross Margin for the quarter ending June 06, 2020 was $98m a 4.74% increase of 5m year over year
  • Adamas Pharma Gross Margin for the last 12 months ending June 06, 2020 was $96m a 1.16% increase of 1m year over year
  • Adamas Pharma Annual Gross Margin for 2019 was $95m a -2.79% decrease of -3m from 2018
  • Adamas Pharma Annual Gross Margin for 2018 was $98m a 1.14% increase of 1m from 2017
  • Adamas Pharma Annual Gross Margin for 2017 was $97m a -3.07% decrease of -3m from 2016
Other Margins & Efficiency Metrics:
  • Adamas Pharma EBITDA Margin for the quarter ending December 12, 2018 was $-187m a 135.57% decrease of -254m year over year
  • Adamas Pharma Return on Capital % for the quarter ending September 09, 2018 was -29.66 a -68.05% increase of 20.18 year over year
  • Adamas Pharma Return on Equity % for the quarter ending September 09, 2018 was -103.21 a -49.69% increase of 51.29 year over year
View Chart On Koyfin

Quarterly ADMS Gross Margin Data

06/2020$98m
03/2020$96m
12/2019$97m
09/2019$93m
06/2019$95m
03/2019$96m
12/2018$97m
09/2018$99m
06/2018$99m
03/2018$99m

Annual ADMS Gross Margin Data

2019$95m
2018$98m
2017$97m
2016$100m
2015$100m
2014$100m
2013$100m
2012$100m
2011$100m